Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Natalizumab · relapsing multiple sclerosis

Rituximab as 'first choice' showed no clear difference in natalizumab compared with other disease‐modifying treatments (low certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.24 [0.06, 1]
170 participants
Low